课题基金 / 基金详情

Prophylactic and therapeutic HPV16 vaccine using yeast expressing chimeric L1 and E7 protein.

Prophylactic and therapeutic HPV16 vaccine using yeast expressing chimeric L1 and E7 protein.
使用表达嵌合 L1 和 E7 蛋白的酵母来预防和治疗 HPV16 疫苗。
批准号:
15591735
负责人:
SASAGAWA Toshiyuki
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

SASAGAWA Toshiyuki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
High-risk HPV, such as HPV type 16 was the most important etiologic factor for cervical cancer, which is the secondary many cancer in women worldwide. Therefore, HPV vaccine development is one of the best ways to reduce the incidence of cervical cancer, especially in manu developing countries Koutsky et al. first demonstrate that HPV16-L1 virus-like particles (VLP), which was produced from yeast can protect HPV16-infection in women who undertook parenteral vaccination of the VLP. This suggests that VLP vaccine is highly effective against HPV16 infection. However, the parenteral VLP vaccine may be not useful in many developing countries, since it is very expensive and the injection procedure may be difficult to perform in such countries where medical stuffs are limited. We have found that an edible freeze-dried yeast vaccine containing HPV16-L1 protein enhanced with intranasal administration of a suboptimal dose of HPV16-VLP is able to induce HPV16-specific antibody responses in mice mo … More del system. In the present study, we tried to make recombinant yeast expressing L1-E7 chimeric protein in order to synthesize VLP containing oncoprotein E7. We made three different-sized L1-E7 DNA constracts which contained full-length of E7 and truncated L1 genes, and transfected them into yeast, and had got three strains of yeast expressing 57kD, 63KD, and 67KD proteins, respectively. Since we succeeded to purify VLP from the yeast producing 63KD protein, we used this strain for an edible yeast vaccine in the mice model system. If the chimeric L1-E7 VLP induced antibody against HP16, and incorporated E7 protein induced cytotoxic T lymphocytes killing HPV16-infected cell, this vaccine might be useful as prophylactic and therapeutic vaccine against HPV16 infection. In the preliminary experiment, we found that this vaccine induces HPV16 L1 antibody in the immunized mice. Now we are going to investigate this further, and to test the cytotoxic T lymphocyte response to HPV16-E7 protein in the mice Less
期刊论文(41)
专著(0)
科研奖励(0)
会议论文
Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation. 412, 13-19, 2003.
G2 DNA 损伤检查点废除后,p53 的缺失会导致 M 期延迟。
DOI: --
发表时间: 2003
期刊: Arch.Biochem.and Biophysics 412
影响因子: --
作者: [Minemoto Y, Uchida S. et al.]
通讯作者: Uchida S. et al.
DOI: --
发表时间: 2003
期刊: Human pathology 34
影响因子: --
作者: [Shimakage M, Kawahara K. et al.]
通讯作者: Kawahara K. et al.
DOI: 10.1016/s0003-9861(03)00010-9
发表时间: 2003-04
期刊: Archives of biochemistry and biophysics
影响因子: 3.9
作者: [Y. Minemoto;Sanae Uchida;M. Ohtsubo;M. Shimura;T. Sasagawa;M. Hirata;H. Nakagama;Y. Ishizaka;K. Yamashita]
通讯作者: Y. Minemoto;Sanae Uchida;M. Ohtsubo;M. Shimura;T. Sasagawa;M. Hirata;H. Nakagama;Y. Ishizaka;K. Yamashita
Sasagawa T, Rose RC, et al.: "Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids"Int J Cancer. 104. 328-335 (2003)
Sasakawa T、Rose RC 等人:“粘膜免疫球蛋白-A 和-G 对致癌人乳头瘤病毒衣壳的反应”Int J Cancer。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
22
    Expression and immunoreactivity of high-risk human papillomavirus E4 prtein
    • 批准号:
      18591827
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.51万
    • 财政年份:
      2006
    • 负责人:
      SASAGAWA Toshiyuki
    • 依托单位:
    ORALLY ADMINISTERED HPV 16 VACCINE STIMULATING GUT-ASSOCIATED LYMPHOID TISSUES
    • 批准号:
      13671701
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $0.64万
    • 财政年份:
      2001
    • 负责人:
      SASAGAWA Toshiyuki
    • 依托单位:
    Study of immunologic evasion of human papllomavirus (HPV) Against host immuno-ersponse in patient with cervical cancer
    • 批准号:
      10671526
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.73万
    • 财政年份:
      1998
    • 负责人:
      SASAGAWA Toshiyuki
    • 依托单位:
    The development of serological test detecting antibodies against oncogenic human papillomaviruses by ELISA
    • 批准号:
      08671877
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.54万
    • 财政年份:
      1996
    • 负责人:
      SASAGAWA Toshiyuki
    • 依托单位:
    海外基金